Anti-Cancer Drug Design

Review. The role of thymidine phosphorylase/PD-ECGF in cancer chemotherapy: a chemical perspective
pp. 383-392(10)
Authors: Cole C.; Foster A.; Freeman S.; Jaffar M.; Murray P.; Stratford I.

A comparative cell-based high throughput screening strategy for the discovery of selective tyrosine kinase inhibitors with anticancer activity
pp. 393-402(10)
Authors: Stratowa C.; Baum A.; Castañon M.; Dahmann G.; Himmelsbach F.; Himmler A.; Loeber G.; Metz T.; Schnitzer R.; Solca F.; Spevak W.; Tontsch U.; von Rüden T.

Structure-based design of potent inhibitors of EGF-receptor tyrosine kinase as anti-cancer agents
pp. 403-410(8)
Authors: Ghosh S.; Narla R.; Zheng Y.; Liu X-P.; Jun X.; Mao C.; Sudbeck E.; Uckun F.

A similarity model for the human angiogenic factor, thymidine phosphorylase/platelet derived-endothelial cell growth factor
pp. 411-420(10)
Authors: Cole C.; Marks D.; Jaffar M.; Stratford I.; Douglas K.; Freeman S.

Parallel syntheses of disulfide inhibitors of the thioredoxin redox system as potential antitumor agents
pp. 421-432(12)
Authors: Kirkpatrick D.; Watson S.; Kunkel M.; Fletcher S.; Ulhaq S.; Powis G.

A DNA binding indolocarbazole disaccharide derivative remains highly cytotoxic without inhibiting topoisomerase I
pp. 433-442(10)
Authors: Qu X.; Chaires J.; Ohkubo M.; Yoshinari T.; Nishimura S.; Bailly C.

The quinobenzoxazines: relationship between DNA binding and biological activity
pp. 443-450(8)
Authors: Kwok Y.; Sun D.; Clement J.; Hurley L.

Pyrimido[4,5,6-kl]acridines. Synthesis, in vitro cytotoxicity and structure-activity relationships
pp. 451-459(9)
Authors: Antonini I.; Polucci P.; Martelli S.